Merck & Co. (MRK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-14
$143.80-0.72%
Close 2026-09-15 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-14
Research Workspace
Put MRK beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Non-GAAP EPS at least $5.04 in 2026: FY26 EPS guidance $2.71 vs $5.04 target.
View ThesisRevenue is growing steadily — about 5% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 13%.
View QualityManagement screens strong on capital allocation, earnings delivery.
View ManagementExpectations look high — the market is pricing in about 68% growth a year, above the roughly 4% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskMerck's growth depends on its oncology pipeline and new product launches. The company must maintain revenue growth despite Keytruda patent concerns. Revenue grew 5% year over year, and the last quarter beat expectations. Merck trades at 45× P/E, while the peer median is 15×. The market expects more growth than we forecast, making it look expensive. A risk is if Merck cuts guidance after raising it recently. This could hurt credibility and lead to a stock drop. Peer multiples imply a price about 67% below where it trades. This read is provisional.
Trailing returns as of 2026-09-15. MRK is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering MRK (as of Sep 2026).
Based on 17 Wall Street analysts offering 12-month price targets for MRK in the last 4 months.
Continue this research
Compare MRK with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MRK Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put MRK next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance and expand oncology pipeline
Supports advancement of oncology pipeline with successful enrollment.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $143.80
The last 12 months of price, then the range of analyst 12-month targets from today’s $143.80.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance and expand oncology pipeline
CEO comments on pipeline upside support oncology expansion.
Advances: Advance and expand oncology pipeline
Growing pipeline supports oncology expansion objective.
Advances: Advance and expand oncology pipeline
Strengthens oncology pipeline ahead of KEYTRUDA exclusivity loss.
Changes in GARDASIL messaging may impact revenue guidance.
Advances: Advance and expand oncology pipeline
Guggenheim's target reflects confidence in oncology pipeline.
Advances: Advance and expand oncology pipeline
Positive trial results support oncology pipeline advancement.
Advances: Advance and expand oncology pipeline
Positive trial results enhance oncology pipeline prospects.